Thursday, 1 September 2005

7:00 p.m. - 10:00 p.m.
Welcome Party at the Marktcafé

Friday, 2 September 2005

8:00 a.m. - 8:05 a.m.
Welcome Address

8:05 a.m. - 8:30 a.m.
Current limitations of IBD treatment: Keynote Lecture
- Where do we go from here?

8:30 a.m. - 10:30 a.m.
Genetics of inflammatory bowel disease - NOD/CARD proteins: Diagnostic and therapeutic consequences?

• NOD2/CARD mutations in Crohn's disease.
  J.P. Hugot, Paris
• Microbial signaling through NOD proteins.
  D. Philpott, Paris
• Functional relevance of NOD2 on cellular signaling in Crohn's disease.
  G. Nunez, Ann Arbor
• Which other susceptibility genes are on the horizon?
  S. Schreiber, Kiel
• Do genetic mutations provide new insights for therapy?
  J. Cho, Chicago

10:30 a.m. - 11:15 a.m.
Coffee Break

11:15 a.m. - 1:15 p.m.
Immunologic abnormalities in IBD - What can we learn from animal models?

• Role of TGF-ß in mucosal inflammation.
  I.J. Fuss, Bethesda
• TNF/TNFR-pathways in chronic inflammation.
  G. Kollias, Athens
• New insights from studies of regulatory T cell populations.
  F. Powrie, Oxford
• Lessons from enteric infections.
  L. Eckmann, San Diego
• The commensal microbial flora: Relevance for intestinal inflammation.
  C.O. Elson, Birmingham

1:15 p.m. - 2:30 p.m.
Lunch Break

2:30 p.m. - 4:00 p.m.
Immunologic disturbances in human IBD - Defining and manipulating the key pathways (Part A)

• Inhibition of chemokine receptors or ligands as a potential approach for treatment?
  I.R. Williams, Atlanta
• Apoptosis as a therapeutic tool in IBD?
  T.F. Kucharzik, Münster
• Leucocyte adhesion molecules - Are they relevant as target for IBD treatment?
  D.B. Binion, Milwaukee
• Novel signal transduction pathways - Relevance for future therapies?
  M.F. Neurath, Mainz

4:00 p.m. - 5:30 p.m.
Accompanying Poster Session

5:30 p.m. - 7:00 p.m.
Immunologic disturbances in human IBD - Defining and manipulating the key pathways (Part B)

• NF-κB signaling -The pros and cons of altering NF-κB as a therapeutic approach.
  L. Egan, Rochester
• The role of the melanocortin system in intestinal inflammation.
  C. Maaser, Münster
• Intracellular targets: A role for inhibition of MAP-kinases in therapy?
  M.P. Peppelenbosch, Amsterdam
• Cytokines - Who are the key players and what is the role for cytokine treatment.
  R.S. Blumberg, Boston

7:00 p.m. - 7:15 p.m.
Concluding Remarks

7:30 p.m.
Departure for Dinner Party

8:00 p.m. - 10:30 p.m.
Dinner Party at Hülshoff Castle

Saturday, 3 September 2005

8:00 a.m. - 10:00 a.m.
Intestinal epithelial cells in IBD - An active barrier?

• Tight junction function and the modulation of paracellular permeability during IBD.
  A. Nusrat, Atlanta
• Epithelial transport under inflammatory conditions - Can it be regulated?
  M.C. Berin, New York
• Molecular mechanisms of disturbed electrolyte transport in inflammatory bowel disorders.
  U. Seidler, Hannover
• Neutrophil transepithelial migration and epithelial barrier function in IBD - Potential targets for inhibiting neutrophil trafficking.
  C.A. Parkos, Atlanta
• Disrupted barrier function through epithelial cell apoptosis?
  J. Schulzke, Berlin
• Growth factors as treatment option of intestinal inflammation.
  B.K. Dieckgraefe, St. Louis

10:00 a.m. - 10:45 a.m.
Coffee Break

10:45 a.m. - 12:45 a.m.
GALT - Relevant for regulation of inflammation?

• Therapeutic drug delivery by genetically modified Lactococcus lactis.
  L. Steidler, Cork Ireland
• Role of lymphotoxins in the developmentof PP and MLN -
  Relevance to intestinal inflammation and treatment.
  T.W. Spahn, Münster
• Antigen presentation by intestinal epithelial cells.
  L.F. Mayer, New York
• Induction of intestinal lymphoid tissue - The role of cryptopatches.
  A. Lügering, Münster
• Peyer's patches and M cells as potential site of the inflammatory onset in Crohn's disease.
  J.D. Soderholm, Linkoping
• Intraepithelial T-cells - Implication for intestinal inflammation.
  M. Kronenberg, San Diego

12:45 a.m. - 2:00 p.m.
Lunch Break

2:00 p.m. - 3:30 p.m.
Relevance of microbial factors - Additive or causative for IBD? (Part A)

• The bacterial weaponry - lessons from Shigella.
  P.J. Sansonetti, Paris
• Microbial - epithelial cell crosstalk during inflammation: the host response.
  M.F. Kagnoff, San Diego
• Defensin deficiency in Crohn's disease.
  E.F. Stange, Stuttgart
• Toll-like receptor signaling and its relevance to intestinal inflammation.
  E. Cario, Essen

3:30 p.m. - 5:00 p.m.
Accompanying Poster Session and Coffee Break

5:00 p.m. - 6:30 p.m.
Relevance of microbial factors - Additive or causative for IBD? (Part B)

• Probiotics - helpful to control intestinal inflammation?
  W. Kruis, Köln
• Immunostimulatory DNA - Potential therapeutics for treatment of enteric inflammatory disease?
  E. Raz, San Diego
• Helminths: What do they teach us about IBD pathogenesis and treatment?
  J.V. Weinstock, Iowa
• Relevance of microbial factors - additive or causative for IBD?
  R. Balfour Sartor, Chapel Hill

6:30 p.m. - 6:45 p.m.
Poster Awards

6:45 p.m. - 7:15 p.m.
Inflammatory Bowel Disease: Keynote Lecture
- Pandora's box, present and future.